Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine in Moderate COVID-19
NCT04718480Phase 2Completed
- Sponsor
- SigmaDrugs Ltd.
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluvoxamine in coronavirus disease 2019 (COVID-19), sponsored by SigmaDrugs Ltd.. Started Nov 2020; status: completed.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04718480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718480.